Clinical trial
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular…
NCT00249795 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00249795 |
|---|---|
| Title | Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I) |
| Official title | A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation |
| Acronym | ACTIVE I |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Cardiovascular Disease |
| Intervention type | Drug |
| Interventions | Irbesartan, placebo |
| Enrollment | 9,016 |
| Start date | Jun 1, 2003 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Nov 7, 2005 |
| Last update posted | Oct 15, 2010 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Finland, France, Germany and 18 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: